This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Avi Kapoor 6 months ago
NewsInitiationMarketsAnalyst RatingsTrading Ideas
Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Stifel analyst Dara Azar initiated coverage on Inhibrx Biosciences Inc (NASDAQ:INBX) with a Buy rating and announced a price target of $150. Inhibrx Biosciences shares closed at $62.35 on Tuesday. See how other analysts view this stock.
- Needham analyst Ami Fadia initiated coverage on MapLight Therapeutics Inc (NASDAQ:MPLT) with a Buy rating and announced a price target of $37. MapLight Therapeutics shares closed at $24.14 on Tuesday. See how other analysts view this stock.
- Stifel analyst Dara Azar initiated coverage on Summit Therapeutics Inc (NASDAQ:SMMT) with a Buy rating and announced a price target of $45. Summit Therapeutics shares closed at $19.22 on Tuesday. See how other analysts view this stock.
- Evercore ISI Group analyst Elizabeth Anderson initiated coverage on Elevance Health Inc (NYSE:ELV) with an In-Line rating and announced a price target of $345. Elevance Health shares closed at $311.83 on Tuesday. See how other analysts view this stock.
Considering buying INBX stock? Here’s what analysts think:
Photo via Shutterstock